Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Chen Katz-Even"'
Autor:
Michael Milyavsky, Shai Izraeli, John E. Dick, Amanda Mitchell, Olga I. Gan, Eric R. Lechman, Eitan Kugler, Adi Zipin-Roitman, Chen Katz-Even, Nour Ershaid, Abed Alkader Yassin, Muhammad Yassin, Nasma Aqaqe
Supplementary Table 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d38cdd05897a9bc033df1cc75fdc4c0
https://doi.org/10.1158/0008-5472.22422524.v1
https://doi.org/10.1158/0008-5472.22422524.v1
Autor:
Michael Milyavsky, Shai Izraeli, John E. Dick, Amanda Mitchell, Olga I. Gan, Eric R. Lechman, Eitan Kugler, Adi Zipin-Roitman, Chen Katz-Even, Nour Ershaid, Abed Alkader Yassin, Muhammad Yassin, Nasma Aqaqe
Supplementary Table 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5bdfefcc69c463f17fb05156aae33d
https://doi.org/10.1158/0008-5472.22422527.v1
https://doi.org/10.1158/0008-5472.22422527.v1
Autor:
Michael Milyavsky, Shai Izraeli, John E. Dick, Amanda Mitchell, Olga I. Gan, Eric R. Lechman, Eitan Kugler, Adi Zipin-Roitman, Chen Katz-Even, Nour Ershaid, Abed Alkader Yassin, Muhammad Yassin, Nasma Aqaqe
Acute leukemia is a rapidly progressing blood cancer with low survival rates. Unfavorable prognosis is attributed to insufficiently characterized subpopulations of leukemia stem cells (LSC) that drive chemoresistance and leukemia relapse. Here we uti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbd22ac8cd34a1c15868cb537e285ada
https://doi.org/10.1158/0008-5472.c.6511256.v1
https://doi.org/10.1158/0008-5472.c.6511256.v1
Autor:
Michael Milyavsky, Shai Izraeli, John E. Dick, Amanda Mitchell, Olga I. Gan, Eric R. Lechman, Eitan Kugler, Adi Zipin-Roitman, Chen Katz-Even, Nour Ershaid, Abed Alkader Yassin, Muhammad Yassin, Nasma Aqaqe
Supplementary figure legends and full list of materials and methods references
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270e9aada8c7fe4abba16775b9befbf3
https://doi.org/10.1158/0008-5472.22422536
https://doi.org/10.1158/0008-5472.22422536
Autor:
Michael Milyavsky, Shai Izraeli, John E. Dick, Amanda Mitchell, Olga I. Gan, Eric R. Lechman, Eitan Kugler, Adi Zipin-Roitman, Chen Katz-Even, Nour Ershaid, Abed Alkader Yassin, Muhammad Yassin, Nasma Aqaqe
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd48f04df86a92c30f33e0369f46b97
https://doi.org/10.1158/0008-5472.22422533.v1
https://doi.org/10.1158/0008-5472.22422533.v1
Autor:
John E. Dick, Muhammad Yassin, Eric R. Lechman, Shai Izraeli, Michael Milyavsky, Amanda Mitchell, Nour Ershaid, Eitan Kugler, Adi Zipin-Roitman, Abed Alkader Yassin, Chen Katz-Even, Olga I. Gan, Nasma Aqaqe
Publikováno v:
Cancer Research. 79:3862-3876
Acute leukemia is a rapidly progressing blood cancer with low survival rates. Unfavorable prognosis is attributed to insufficiently characterized subpopulations of leukemia stem cells (LSC) that drive chemoresistance and leukemia relapse. Here we uti
Publikováno v:
Experimental Hematology. 111:S115
Autor:
Nasma, Aqaqe, Muhammad, Yassin, Abed Alkader, Yassin, Nour, Ershaid, Chen, Katz-Even, Adi, Zipin-Roitman, Eitan, Kugler, Eric R, Lechman, Olga I, Gan, Amanda, Mitchell, John E, Dick, Shai, Izraeli, Michael, Milyavsky
Publikováno v:
Cancer research. 79(15)
Acute leukemia is a rapidly progressing blood cancer with low survival rates. Unfavorable prognosis is attributed to insufficiently characterized subpopulations of leukemia stem cells (LSC) that drive chemoresistance and leukemia relapse. Here we uti
Autor:
Eric R. Lechman, Michael Milyavsky, John E. Dick, Nour Ershaid, Adi Zipin-Roitman, Abed Alkader Yassin, Muhammad Yassin, Eitan Kugler, Amanda Mitchell, Chen Katz-Even, Shai Izraeli, Olga I. Gan, Nasma Aqaqe
Publikováno v:
Experimental Hematology. 76:S78
Acute leukemia is a rapidly progressing blood cancer with low survival rates. Unfavorable prognosis is attributed to the insufficiently characterized subpopulations of Leukemia Stem Cells (LSCs) that drive chemoresistance and leukemia relapse. Here w